XERS Xeris Biopharma Holdings, Inc.

NASDAQ
$7.45

Xeris Biopharma Holdings, Inc. (XERS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with XERS's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 3 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
8
18 transactions
Purchases
$0
0 shares
Sales
$2.6M
352,333 shares
Net activity
-$2.6M
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $2.6M 18 transactions · 352,333 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $722.5K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Hecht Beth See Remarks Sell 10b5-1 16,666 $8.49 $141.4K 1,127,796 −1.5% of holding
McCulloch Kevin See Remarks Sell 10b5-1 15,000 $8.49 $127.3K 1,639,208 −0.9% of holding
Pieper Steven See Remarks Sell 10b5-1 5,000 $8.50 $42.5K 1,356,053 −0.4% of holding
Pieper Steven See Remarks Sell 10b5-1 5,000 $8.50 $42.5K 1,361,053 −0.4% of holding
Hecht Beth See Remarks Sell 10b5-1 16,666 $8.01 $133.6K 1,144,462 −1.4% of holding
McCulloch Kevin See Remarks Sell 10b5-1 15,000 $8.02 $120.2K 1,676,126 −0.9% of holding
Pieper Steven See Remarks Sell 10b5-1 27,600 $8.52 $235.3K 1,366,053 −2% of holding
Pieper Steven See Remarks Sell 10b5-1 17,400 $8.50 $147.9K 1,393,653 −1.2% of holding
McCulloch Kevin See Remarks Sell 10b5-1 90,000 $8.03 $722.5K 1,691,126 −5.1% of holding
Hecht Beth See Remarks Sell 10b5-1 16,666 $8.03 $133.9K 1,161,128 −1.4% of holding
HALKUFF DAWN Director Sell 10b5-1 20,000 $6.09 $121.9K 95,000 −17.4% of holding
BORMANN-KENNEDY BARBARA-JEAN ANNE Director Sell 10b5-1 16,000 $6.09 $97.5K 126,500 −11.2% of holding
JOHNSON JOHN Director Sell 10b5-1 15,000 $6.09 $91.4K 683,083 −2.1% of holding
PERSKY MARLA Director Sell 10b5-1 15,500 $5.90 $91.4K 126,500 −10.9% of holding
Hecht Beth See Remarks Sell 10b5-1 16,667 $6.06 $101.0K 1,176,506 −1.4% of holding
Hecht Beth See Remarks Sell 10b5-1 16,667 $6.23 $103.8K 1,193,173 −1.4% of holding
Hecht Beth See Remarks Sell 10b5-1 16,667 $5.99 $99.9K 1,209,840 −1.4% of holding
Brady James Aloysius Director Sell 10b5-1 10,834 $5.54 $60.0K 89,166 −10.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.